Novaliq GmbH-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Novaliq GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013966
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Novaliq GmbH (Novaliq) is a drug delivery company that develops pharmaceutical formulations. The company develops novel ophthalmic and dermatological products, and solutions for organ preservation based on the physicochemical properties of semifluorinated alkanes. It offers NovaTears, a preservative free eye drop product for the relief of discomfort under dry eye syndrome. Novaliq also has products in pipeline for the treatment of glaucoma and other retinal diseases. The company offers its SFA technology as a delivery platform for external co-development cooperations. It licenses its SFA technology to distribution partners who completes registration studies. Novaliq is headquartered in Heidelberg, Germany.

Novaliq GmbH – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Novaliq GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Novaliq GmbH, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Novaliq GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Novaliq GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Novaliq GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Novaliq GmbH, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Novaliq Raises US$18 Million In Venture Financing 10
Novaliq Raises US$5.2 Million In Venture Financing 11
Novaliq Secures US$3.32 Million In Venture Financing 12
Partnerships 13
Novaliq Enters into Partnership with University of Cologne 13
Licensing Agreements 14
AFT Pharma Enters into Licensing Agreement with Novaliq 14
URSAPHARM Enters into Licensing Agreement with Novaliq 15
Novaliq GmbH – Key Competitors 16
Novaliq GmbH – Key Employees 17
Novaliq GmbH – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Corporate Communications 19
Jun 27, 2017: NOVALIQ Strengthens Executive Management Team with the Appointment of Gabriela Burian, MD, MPH, as Chief Medical Officer 19
Oct 06, 2016: Novaliq Strengthens Executive Management Team by Appointing Christian Roesky, PhD, as Chief Executive Officer 20
Clinical Trials 21
Jan 05, 2017: Novaliq Announces Positive Topline Results of Phase 2 Clinical Trial Evaluating CyclASol in Adults with Moderate to Severe Dry Eye Disease 21
May 05, 2016: Novaliq Announces Last Patient Enrolled in Phase 2 Clinical Trial of CyclASol for the Treatment of Moderate to Severe Dry Eye Disease 22
Feb 16, 2016: Novaliq Begins Phase 2 Clinical Trial of CyclASol for the Treatment of Moderate to Severe Dry Eye Disease 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Novaliq GmbH, Pharmaceuticals & Healthcare, Key Facts 2
Novaliq GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Novaliq GmbH, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Novaliq GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Novaliq GmbH, Deals By Therapy Area, 2011 to YTD 2017 8
Novaliq GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Novaliq Raises US$18 Million In Venture Financing 10
Novaliq Raises US$5.2 Million In Venture Financing 11
Novaliq Secures US$3.32 Million In Venture Financing 12
Novaliq Enters into Partnership with University of Cologne 13
AFT Pharma Enters into Licensing Agreement with Novaliq 14
URSAPHARM Enters into Licensing Agreement with Novaliq 15
Novaliq GmbH, Key Competitors 16
Novaliq GmbH, Key Employees 17

★海外企業調査レポート[Novaliq GmbH-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cathay Life Insurance Co Ltd:企業の戦略・SWOT・財務分析
    Cathay Life Insurance Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Cathay Life Insurance Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Arise AB (ARISE):企業の財務・戦略的SWOT分析
    Arise AB (ARISE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • APEIRON Biologics AG:製薬・医療:M&Aディール及び事業提携情報
    Summary APEIRON Biologics AG (APEIRON) is a clinical-stage biotechnology company that concentrates on the development of biological and immunological solutions for the treatment of various cancers. The company’s pipeline products include APN01, APN301, APN311, APN401, APN411, APN421 and APN431. Its …
  • Volta River Authority:企業の戦略的SWOT分析
    Volta River Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Continuum Wind Energy Ltd-エネルギー分野:企業M&A・提携分析
    Summary Continuum Wind Energy Ltd (Continuum Wind Energy), a subsidiary of Morgan Stanley Infrastructure Partners LP is a renewable energy company that constructs and develops wind farms and wind energy generation. The company's services include optimization of number of wind turbines to maximize ge …
  • Takara Bio Inc (4974):製薬・医療:M&Aディール及び事業提携情報
    Summary Takara Bio Inc (Takara), a subsidiary of Takara Holdings Inc, is a biotechnology company that develops, manufactures and distributes biotechnology research reagents and equipments for life sciences research. The company sells gene amplification system and offers scientific instruments. It of …
  • Elite Pharmaceuticals Inc (ELTP):企業の財務・戦略的SWOT分析
    Elite Pharmaceuticals Inc (ELTP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Apache Corp (APA):石油・ガス:M&Aディール及び事業提携情報
    Summary Apache Corp (Apache) is an independent upstream energy company, which carries out exploration, development and production of natural gas, crude oil and natural gas liquids (NGLs). It has onshore and offshore asset base consisting of operations in the Permian Basin, the Anadarko basin in west …
  • Safety-Kleen Inc:企業の戦略的SWOT分析
    Safety-Kleen Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Uzma Bhd (UZMA):企業の財務・戦略的SWOT分析
    Summary Uzma Bhd (Uzma) is an oil and gas service and equipment company. The company provides integrated solutions to the upstream sector. It offers geoscience and petroleum engineering, laboratory solutions, drilling and well services, production operation and optimization, manpower consultancy and …
  • Agilent Technologies Inc (A):企業の財務・戦略的SWOT分析
    Agilent Technologies Inc (A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Graftobian Makeup Company:企業の戦略・SWOT・財務情報
    Graftobian Makeup Company - Strategy, SWOT and Corporate Finance Report Summary Graftobian Makeup Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • ImmusanT Inc-医療機器分野:企業M&A・提携分析
    Summary ImmusanT Inc (ImmusanT) is a drug company that discovers and develops therapies for celiac disease. The company’s pipeline products include Nexvax 2 and Nexvax 3. Its pipeline product Nexvax 2 is used for treating, preventing and diagnosing celiac disease. ImmusanT’s pipeline products are al …
  • Bata India Limited:企業の戦略・SWOT・財務分析
    Bata India Limited - Strategy, SWOT and Corporate Finance Report Summary Bata India Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • AF Gruppen ASA (AFG):企業の財務・戦略的SWOT分析
    AF Gruppen ASA (AFG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Versartis Inc (VSAR):製薬・医療:M&Aディール及び事業提携情報
    Summary Versartis Inc (Versartis) is a biopharmaceutical company that develops, manufactures and commercializes medicines for the treatment of endocrine disorders. The company’s lead product candidate include somavaratan (VRS-317) is a recombinant human growth hormone (GHD) that is designed to reduc …
  • Cedars-Sinai Medical Center-製薬・医療分野:企業M&A・提携分析
    Summary Cedars-Sinai Medical Center (Cedars-Sinai), formerly Kaspare Cohn Hospital is an academic and medical center that provides healthcare services for patients and medical professionals, and research and education services. The center offers treatments for various conditions such as abdominal pa …
  • Generex Biotechnology Corp (GNBT):製薬・医療:M&Aディール及び事業提携情報
    Summary Generex Biotechnology Corp (Generex) carries out the research, development and commercialization of drug delivery systems and technologies. It developed a proprietary platform technology to deliver drugs into the human body through the oral cavity. The company’s proprietary liquid formulatio …
  • Oilex Ltd (OEX):企業の財務・戦略的SWOT分析
    Summary Oilex Ltd (Oilex) is an oil and gas company that acquires, explores and develops petroleum resources. The company’s projects in Australia include STP-EPA-0106, STP-EPA-0131, and STP-EPA-0107. Its STP-EPA-0106 project is located in onshore north-western Australia. Oilex’s Indian projects are …
  • Gammon Infrastructure Projects Ltd (GAMMNINFRA):企業の財務・戦略的SWOT分析
    Gammon Infrastructure Projects Ltd (GAMMNINFRA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key st …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆